HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced today that the Company entered into two separate agreements with Novartis Pharmaceutical Corporation (“Novartis”). The Research Services Agreement establishes a collaboration to develop a family of biomarkers associated with circulating tumor cells (CTCs) that may be useful in determining the efficacy of certain cancer therapies in development by Novartis.
